Cancers | Free Full-Text | HDAC Inhibitors in Acute Myeloid Leukemia | HTML
Marine Drugs | Free Full-Text | Marine Power on Cancer: Drugs, Lead Compounds, and Mechanisms | HTML
The targeted histone deacetylase inhibitor tefinostat (CHR-2845) shows selective in vitro efficacy in monocytoid-lineage leukaem
Valproic acid enhances the antileukemic effect of cytarabine by triggering cell apoptosis
Blood Spotlight Sense and nonsense of high-dose cytarabine for acute myeloid leukemia | Semantic Scholar
![PDF] Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/094147101525dbcb98a9d514f1a305a20a3a7f7c/3-Table1-1.png "PDF] Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. | Semantic Scholar")
PDF] Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. | Semantic Scholar
PDF) Inhibition of Histone Deacetylases 1 and 6 Enhances Cytarabine-Induced Apoptosis in Pediatric Acute Myeloid Leukemia Cells | Larry Matherly - Academia.edu
Role of HDACs in normal and malignant hematopoiesis
A Randomized Comparison of Modified Intermediate-dose Ara-C versus High-dose Ara-C in Post-remission Therapy for Acute Myeloid Leukemia | Anticancer Research
Cancer Management Chapter 29: Acute leukemias
A: RFS and (B) OS of 130 patients given ARA-C at standard dose (SDAC,... | Download Scientific Diagram
HDAC Inhibitors Act with 5-aza-2′-Deoxycytidine to Inhibit Cell Proliferation by Suppressing Removal of Incorporated Abases in Lung Cancer Cells | PLOS ONE
V_Hematology_Forum_Prof_Lowenberg
A Randomized Investigation of High-Dose Versus Standard-Dose Cytosine Arabinoside With Daunorubicin in Patients With Previously Untreated Acute Myeloid Leukemia: A Southwest Oncology Group Study - ScienceDirect
HDAC5 catalytic activity suppresses cardiomyocyte oxidative stress and NRF2 target gene expression - Journal of Biological Chemistry
A Randomized Comparison of Modified Intermediate-dose Ara-C versus High-dose Ara-C in Post-remission Therapy for Acute Myeloid Leukemia | Anticancer Research
Efficacy of high-dose cytarabine and aclarubicin in combination with G-CSF regimen compared to intermediate/high-dose cytarabine and standard-dose cytarabine induction regimen for non-remission acute myeloid leukemia Lei M, Liu L, Wang Z, Wu
Cytarabine (Cytosine β-D-arabinofuranoside) | DNA Synthesis Inhibitor | MedChemExpress
Targeting HDAC3, a new partner protein of AKT in the reversal of chemoresistance in acute myeloid leukemia via DNA damage response | Leukemia
A new pattern of cytosineâ•'arabinosideâ•'induced lung toxicity
The combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia | Nature Communications
HDAC - high-dose ara-C
Epigenetic therapies in acute myeloid leukemia: the role of hypomethylating agents, histone deacetylase inhibitors and the combination of hypomethylating agents with histone deacetylase inhibitors. - Abstract - Europe PMC
Romidepsin enhances the efficacy of cytarabine in vivo, revealing histone deacetylase inhibition as a promising therapeutic strategy for KMT2A-rearranged infant acute lymphoblastic leukemia | Haematologica
Ribonucleotide reductase inhibitors suppress SAMHD1 ara‐CTPase activity enhancing cytarabine efficacy | EMBO Molecular Medicine
